Origin Therapeutics is an actively managed investment issuer providing investors with diverse exposure to the psychedelic industry, offering capital expertise and board representation to early stage startups.
Alfred Wong, Vice President of Investments for Origin, joined last month’s Psychedelic Capital event.
“How is Origin different from a private venture capital firm? The the answer is that we don’t charge a management fee or performance fee. The company is fully incentivized through stock options and by being shareholders of Origin as well.”
It’s a different approach from your traditional VC model. Origin Therapeutics is working towards a public listing on the stock market, which would give the public access to early-stage investment opportunities, something most retail investors are not able to do.
See the press release on their preliminary prospectus and proposed listing on the CSE (proposed ticker ORIG)
“Why not let retail investors get the upside by putting capital alongside other VC’s? So for retail investors investing in Origin they get access to some of the deals that they would otherwise not have, and we mitigate the risk with our team’s due diligence, providing continued growth support to our investee companies to ensure success.”
An interesting value proposal, as the majority of early-stage opportunities are heavily-barriered for the average investor. Mr. Wong then went on to review some of Origin’s early-stage investments.
Dimensions Health is focused on developing psychedelic inspired retreats, starting with its flagship property in Maple Lake, Ontario. Origin invested in Dimension’s initial seed round and provided guidance on its real estate financing initiatives. Dimensions is currently raising $12.5M in its Series A round, representing a 3x unrealized return on Origin’s initial investment.
TripSitter is an oral ketamine treatment program delivered online by licensed physicians. TripSitter’s program provides deep and sustained relief for both mild and severe depression, anxiety, and trauma-related mental health conditions.
See their full investment portfolio here https://originpsychedelics.com/portfolio/
Full disclosure, Origin is also an early investor in Microdose Psychedelic Insights.
For more information, here’s a link to their full investor presentation
https://originpsychedelics.com/wp-content/uploads/2021/11/Origin-Presentation-V28.pdf
